PROJECT HELIX-HTT | Huntington’s-Adjacent Neuro-Oncology Vaccine Program | SCF Vaccine Candidate Package (VCP)

D-WS6-001

SCF Vaccine Candidate Package (VCP)

PROJECT HELIX-HTT | Huntington’s-Adjacent Neuro-Oncology Vaccine Program

DOCUMENT CONTROL HEADER

Program Code: SCF-ARGEN-HTT-NO-01

Workflow Stage: Discovery Phase Completion

Deliverable: Core Deliverable #8 (Final)

Document Code: SCF-VCP-NO-0001

Purpose: Integrate all Discovery Phase outputs into a complete vaccine development package suitable for preclinical advancement and future IND planning.

1. EXECUTIVE SUMMARY

The SCF Vaccine Candidate Package represents the final output of the Discovery Phase.

It integrates:

Mutation Catalog (MCAT)
Expression Atlas (EXAT)
HLA Compatibility Matrix (HCM)
Presented Antigen Library (PAL)
SCF Microenvironment Report (MES)
Ranked Antigen Candidate Library (RACL)

into a unified therapeutic vaccine design package.

2. VACCINE DEVELOPMENT OBJECTIVE

Primary Goal

Generate durable anti-tumor immunity against neuro-oncology targets while maintaining CNS safety.

Secondary Goals

Maximize antigen visibility
Minimize immune escape
Maintain neuroimmune compatibility
Enable personalized vaccine deployment

3. FINAL ANTIGEN COMPOSITION STRATEGY

Vaccine Core Structure

Tier I — Primary Antigen Set

Target:

8–20 antigens

Composition:

Antigen Type	Target Allocation
Personalized Neoantigens	60–70%
Fusion Antigens	10–20%
Tumor-Associated Antigens	10–20%

Tier II — Backup Antigen Set

Target:

3–5 antigens

Purpose:

Antigen replacement
Immune escape mitigation
Manufacturing flexibility

Tier III — SCF Experimental Antigens

Target:

1–3 antigens

Examples:

DNA repair stress antigens
Repeat-instability antigens
Neuroimmune adaptation antigens
Hypoxia-adaptation antigens

Research use only.

4. VACCINE CONSTRUCT ARCHITECTURES

Platform A

Synthetic Long Peptide Vaccine

Advantages:

Simpler manufacturing
Broad HLA presentation
Established oncology precedent

Use:

Early-stage preclinical program

Platform B

mRNA Vaccine

Advantages:

Rapid iteration
Personalized manufacturing
Multi-antigen capability

Use:

Personalized vaccine development

Platform C

Dendritic Cell Vaccine

Advantages:

Strong antigen presentation
High immune activation

Use:

High-risk or refractory disease programs

5. ADJUVANT STRATEGY FRAMEWORK

Objectives

Enhance:

Antigen presentation
T-cell activation
Memory formation

Preferred Adjuvant Categories

Category	Function
TLR agonists	Innate activation
STING agonists	Interferon induction
Dendritic-cell activators	APC enhancement
Cytokine-support systems	Immune amplification

Exclusion Criteria

Avoid:

Excessive neuroinflammation
CNS autoimmunity risk
Persistent inflammatory activation

6. COMPANION DIAGNOSTIC PACKAGE

Required Companion Diagnostics

CDx-01

Antigen Eligibility Panel

Purpose:

Confirm antigen presence

CDx-02

HLA Compatibility Panel

Purpose:

Confirm vaccine compatibility

CDx-03

Immune Response Panel

Markers:

CD8
IFNγ
Granzyme B

CDx-04

SCF Microenvironment Panel

Markers:

Hypoxia
Redox stress
Immune suppression

CDx-05

Neuroimmune Safety Panel

Markers:

Microglial activation
Neuroinflammation
Cytokine balance

7. PRECLINICAL DEVELOPMENT BLUEPRINT

Module 1

Antigen Validation

Objectives:

Confirm antigen identity
Confirm presentation

Success Criteria:

✓ Reproducible detection

✓ Stable expression

Module 2

Immune Activation Studies

Objectives:

CD8 activation
CD4 activation

Endpoints:

Cytokine release
Cytotoxicity
Memory generation

Module 3

Tumor-Killing Studies

Objectives:

Determine:

Tumor cell elimination
Antigen-specific killing

Module 4

Neuroimmune Safety Assessment

Objectives:

Monitor:

Neurotoxicity
Microglial activation
Autoimmunity risk

8. SCF VACCINE SUCCESS METRICS

Vaccine Potency Index (VPI)

Measures:

Antigen coverage
Immune activation
Presentation quality

Immune Durability Index (IDI)

Measures:

Memory formation
Persistence

CNS Compatibility Index (CCI)

Measures:

Neuroimmune safety
Autoimmune risk

SCF Composite Vaccine Score

CVS =
Potency
+
Durability
+
Microenvironment Compatibility
+
Safety

9. DEVELOPMENT DECISION FRAMEWORK

GO

Criteria:

✓ Strong antigen package

✓ Adequate immune activation

✓ Acceptable safety

✓ Favorable MES

CONDITIONAL GO

Criteria:

✓ Correctable microenvironment barriers

✓ Moderate immune suppression

✓ Limited antigen coverage gaps

NO-GO

Criteria:

✗ Severe neurotoxicity risk

✗ Presentation failure

✗ Dominant immune escape

✗ MES-D classification

10. PRE-IND DEVELOPMENT ROADMAP

Stage 1

Antigen Confirmation

↓

Stage 2

Immune Activation Studies

↓

Stage 3

Tumor Killing Assays

↓

Stage 4

Safety Pharmacology

↓

Stage 5

GLP Toxicology

↓

Stage 6

Pre-IND Package

↓

Stage 7

IND Submission Planning

11. SCF THERAPEUTIC VACCINE MASTER PACKAGE

Discovery Outputs Incorporated

✓ Multi-Omics Dataset

✓ Mutation Catalog

✓ Expression Atlas

✓ HLA Compatibility Matrix

✓ Presented Antigen Library

✓ SCF Microenvironment Report

✓ Ranked Antigen Candidate Library

Development Outputs Enabled

✓ Vaccine construct design

✓ Companion diagnostics

✓ Preclinical pharmacology

✓ Safety development

✓ IND planning

12. DISCOVERY PHASE COMPLETION SUMMARY

The Discovery Phase successfully establishes:

Biological Intelligence Layer

Tumor mutations
Expression programs
Antigen presentation

Immunologic Intelligence Layer

HLA compatibility
Presented antigens
Immune activation potential

SCF Intelligence Layer

RHENOVA microenvironment analysis
Neuroimmune compatibility
Vaccine readiness assessment

Translational Layer

Ranked vaccine candidates
Development pathway
IND-enabling foundation

FINAL STATUS

Core Deliverable #8: COMPLETE

Discovery Phase Status

✅ Multi-Omics Dataset Complete

✅ Mutation Catalog Complete

✅ Expression Atlas Complete

✅ HLA Compatibility Matrix Complete

✅ Presented Antigen Library Complete

✅ SCF Microenvironment Report Complete

✅ Ranked Antigen Candidate Library Complete

✅ Vaccine Candidate Package Complete

NEXT PROGRAM PHASE

Phase II — Preclinical Vaccine Development Program

Recommended sequence:

Antigen Validation & Confirmation Studies
Vaccine Construct Engineering Package
Adjuvant Selection & Optimization Package
Dendritic Cell Activation Assays
T-Cell Activation & Cytotoxicity Assays
Tumor Killing Models
Neuroimmune Safety Program
IND-Enabling Vaccine Pharmacology Package

PROJECT HELIX-HTT Discovery Phase: COMPLETE.